预约演示
更新于：2025-08-13
Omeprazole
奥美拉唑
更新于：2025-08-13
概要
基本信息
简介Omeprazole是一种质子泵抑制剂(PPI)，常用于治疗胃肠道疾病，如胃食管反流病(GERD)、消化性溃疡和Zollinger-Ellison综合征。它通过抑制胃壁壁细胞产生胃酸来发挥作用。Omeprazole以口服剂型供应，患者通常耐受性良好。然而，可能会出现头痛、腹泻和腹痛等副作用。作为研究和开发研究人员，需要注意的是，目前正在研究Omeprazole在治疗哮喘和骨质疏松症等其他疾病方面的潜在用途，因为它在临床前和临床研究中显示出了良好的效果。这些研究的结果有望促进Omeprazole的进一步临床应用和发展。 |
药物类型 小分子化药 |
别名 Aomeilazuo Changrong Jiaonang、Omeprazole (JP17/USP/INN)、Omeprezole + [36] |
作用方式 抑制剂 |
作用机制 质子泵抑制剂 |
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C17H19N3O3S |
InChIKeySUBDBMMJDZJVOS-UHFFFAOYSA-N |
CAS号73590-58-6 |
关联
522
项与 奥美拉唑 相关的临床试验NCT06383338
A Prospective Feasibility Study Investigating PhEnoconversion of CYP3A4, CYP2C19 and CYP2D6 Genotype in Paediatric and Adolescent and Young Adult patientS With an acUte diagnosiS of Hodgkin or Non-Hodgkin Lymphoma.
NCT07040839
Comparative Efficacy of Omeprazole and Vonoprazan in the Treatment of Helicobacter Pylori Infection
NCT06690164
Study on the Effect of Atorvastatin Co-administered With Omeprazole on Statin Lactone (SEACOL)
100 项与 奥美拉唑 相关的临床结果
登录后查看更多信息
100 项与 奥美拉唑 相关的转化医学
登录后查看更多信息
100 项与 奥美拉唑 相关的专利（医药）
登录后查看更多信息
12,725
项与 奥美拉唑 相关的文献（医药）2026-01-01TALANTA
Programmable flow heart cutting solid phase extraction using polydopamine coated microfibrous sorbent as a front-end to UHPLC for direct determination of xenobiotic residues in surface water
Article
作者: Chocholouš, Petr ; Erben, Jakub ; Holec, Pavel ; Šatínský, Dalibor ; Chocholoušová Havlíková, Lucie ; Švec, František
Automation and hyphenation of multiple steps were used for the sensitive determination of xenobiotic residues in surface waters. The online hyphenated sequential injection analysis instrumentation used surface-modified microfibrous sorbent for the effective solid phase extraction of 1.0 mL of sample into 100 μL zone, then subjected to the reversed-phase ultra-high performance liquid chromatography (SIA-SPE-UHPLC). The SPE column was packed with polypropylene microfibers and coated with polydopamine by rinsing with the dopamine solution. The freshly prepared column was used for highly reproducible extraction of more than 200 samples in the SIA-SPE-UHPLC method. The matrix calibration covered the expected range with limits of detection in the range 0.1-0.9 μg/L. The method precision was <13 % RSD (at 3 concentration levels), and the method accuracy was in the range 86.5-114.8 %. The sample throughput of the method was 5 samples/hour when the separation took 12 min, including a 5 min SPE step of the next sample run in parallel. The performance of the developed method was demonstrated with the analysis of fifteen river water samples spiked with eleven residues of xenobiotics (ivermectin, fenbendazole, praziquantel, ibuprofen, diclofenac, 17α-ethynylestradiol, androstenedione, carbamazepine, omeprazole, sotalol, and caffeine) at the levels typical for such monitoring. Initial sample treatment prior to the automated analysis consisted only of methanol addition, pH adjustment, and centrifugation. The innovations in the manifold and process that contribute to the modern and effective analysis of environmental samples are discussed.
2025-12-31Gut Microbes
Proton-pump inhibitors increase
C. difficile
infection risk by altering pH rather than by affecting the gut microbiome based on a bioreactor model
Article
作者: Schumacher, Julia ; Faber, Franziska ; Sulzer, Johannes ; Müller, Patrick ; Maier, Lisa ; Molitor, Bastian
Clostridioides difficile infections often occur after antibiotic use, but they have also been linked to proton-pump inhibitor (PPI) therapy. The underlying mechanism - whether infection risk is due to a direct effect of PPIs on the gut microbiome or changes in gastrointestinal pH - has remained unclear. To disentangle both possibilities, we studied the impact of the proton-pump inhibitor omeprazole and pH changes on key members of the human gut microbiome and stool-derived microbial communities from different donors in vitro. We then developed a custom multiple-bioreactor system to grow a model human microbiome community and a stool-derived community in chemostat mode and tested the effects of omeprazole exposure, pH changes, and their combination on C. difficile growth within these communities. Our findings show that changes in pH significantly affect the gut microbial community's biomass and the abundances of different bacterial taxa, leading to increased C. difficile growth within the community. However, omeprazole treatment alone did not result in such effects. These findings imply that the higher risk of C. difficile infection following proton-pump inhibitor therapy is probably because of alterations in gastrointestinal pH rather than a direct interaction between the drug and the microbiome. This understanding offers a new perspective on infection risks in proton-pump inhibitor therapy.
2025-12-31Future Science OA
Comparison of bismuth and concomitant therapy for
H. pylori
eradication: a prospective, randomized clinical trial
Article
作者: Bouali, R. ; Abdelli, M.N. ; Mohamed, G. ; Ben Abdallah, H. ; Oueslati, A. ; Bizid, S. ; Bostani, S. ; Boughoula, K.
BACKGROUND:
In Tunisia, concomitant quadruple therapy (QTC) has been the standard first-line treatment for Helicobacter pylori (H. pylori) infection. However, increasing resistance to clarithromycin (28%) has raised concerns about its long-term efficacy. Bismuth-based quadruple therapy (QTB) offers an alternative, yet its higher cost and safety profile remain debated. This study aimed to compare the efficacy, safety, and cost of both regimens.
METHODS:
We conducted a prospective, randomized, open-label study enrolling 200 patients naïve to any anti-HP treatment. Patients were randomized to either 10 days of bismuth therapy (QTB: potassium bismuth subcitrate, metronidazole, and tetracycline hydrochloride, omeprazole) or 14 days of concomitant quadruple therapy (QTC: amoxicillin, clarithromycin, metronidazole, esomeprazole). H. pylori eradication as defined by a negative urea breath test 4-6 weeks after treatment.
RESULTS:
Among 200 patients, the intention-to-treat eradication rate was 82% for QTC and 87% for QTB (p = 0.29); per-protocol rates were 84.53% and 89.58%, respectively (p = 0.39). Compliance was high (97% in QTC vs 96% in QTB; p = 0.32). Adverse events were similar between groups (61.85% for QTB vs 69% for QTC; p = 0.29).
CONCLUSION:
Bismuth and concomitant quadruple therapies were comparable in terms of efficacy and safety but didn't achieve the accepted minimum eradication rate (90%).
100 项与 奥美拉唑 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 胃灼热 | 美国 | 2017-07-05 | |
| 良性胃溃疡 | 美国 | 2004-02-23 | |
| 糜烂性食管炎 | 澳大利亚 | 2001-12-20 | |
| 吻合口溃疡 | 日本 | 1991-01-18 | |
| 反流性食管炎 | 日本 | 1991-01-18 | |
| 消化性溃疡 | 日本 | 1991-01-18 | |
| 腺癌 | 美国 | 1989-09-14 | |
| 幽门螺杆菌感染 | 美国 | 1989-09-14 | |
| 系统性肥大细胞增多症 | 美国 | 1989-09-14 | |
| 十二指肠溃疡 | 中国 | 1988-12-31 | |
| 内分泌腺肿瘤 | 中国 | 1988-12-31 | |
| 胃食管反流 | 中国 | 1988-12-31 | |
| 胃溃疡 | 中国 | 1988-12-31 | |
| Zollinger-Ellison综合征 | 中国 | 1988-12-31 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 上消化道出血 | 临床3期 | 中国 | 2006-08-01 | |
| 非糜烂性胃食管反流病 | 临床3期 | 日本 | 2003-10-01 | |
| 非糜烂性胃食管反流病 | 临床3期 | 日本 | 2003-10-01 | |
| 非糜烂性反流病 | 临床3期 | 日本 | 2003-10-01 | |
| 非糜烂性反流病 | 临床3期 | 日本 | 2003-10-01 | |
| 早期胃癌 | 临床1期 | 中国 | 2020-06-13 | |
| 胃泌素瘤 | 临床1期 | 中国 | 2020-06-13 | |
| 幽门螺杆菌相关性胃炎 | 临床1期 | 中国 | 2020-06-13 | |
| 边缘区B细胞淋巴瘤 | 临床1期 | 中国 | 2020-06-13 | |
| 免疫性血小板减少症 | 临床1期 | 中国 | 2020-06-13 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 19 | (Omeprazole) | 齋鏇簾築選糧築鏇製願(廠廠窪構艱獵鹽網鏇壓) = 選築鹹範醖糧膚願窪範 壓蓋網顧齋願鏇網淵廠 (襯淵糧壓憲簾獵獵醖遞, 20) 更多 | - | 2024-04-30 | ||
Placebo oral capsule (Placebo) | 齋鏇簾築選糧築鏇製願(廠廠窪構艱獵鹽網鏇壓) = 艱艱製製觸衊構鑰網簾 壓蓋網顧齋願鏇網淵廠 (襯淵糧壓憲簾獵獵醖遞, 16) 更多 | ||||||
临床1期 | 16 | (IRX-2 Regimen -Early Stage Breast Cancer) | 膚醖餘遞窪襯憲窪鹹範 = 窪淵壓糧繭蓋顧製窪網 鹽壓餘鑰簾窪鑰齋築膚 (窪齋膚壓膚鏇衊壓構艱, 顧網顧壓構願壓餘糧鏇 ~ 壓構鑰顧廠襯觸繭鹽淵) 更多 | - | 2024-01-30 | ||
(IRX-2 Regimen -Triple Negative Breast Cancer) | 膚醖餘遞窪襯憲窪鹹範 = 簾願襯壓醖膚壓積遞夢 鹽壓餘鑰簾窪鑰齋築膚 (窪齋膚壓膚鏇衊壓構艱, 鏇襯膚獵蓋築製憲構窪 ~ 壓襯糧構鹽選鏇積鏇選) 更多 | ||||||
N/A | 7 | (Omeprazole (Suspension)) | 淵繭築廠憲選鹽製獵願(製糧淵選願艱窪觸醖繭) = 遞鹹醖衊淵觸遞鬱膚壓 淵醖築簾夢憲窪艱餘膚 (壓願夢鏇窪繭糧夢鏇獵, 襯簾網願膚獵壓糧鏇獵 ~ 憲膚夢淵鏇鑰膚製鏇鹽) 更多 | - | 2023-12-26 | ||
Lifestyle Modification (Lifestyle Modification) | 淵繭築廠憲選鹽製獵願(製糧淵選願艱窪觸醖繭) = 蓋膚憲膚願憲鹹構艱鑰 淵醖築簾夢憲窪艱餘膚 (壓願夢鏇窪繭糧夢鏇獵, 遞窪願鬱憲襯餘鑰製積 ~ 鹽淵鬱鑰製鑰構廠顧鏇) 更多 | ||||||
临床1期 | - | 18 | (Treatment A: ALXN1840 (Fasted)) | 夢醖壓壓艱襯獵鹽餘膚(淵築積壓蓋艱鬱壓餘獵) = 壓願鏇鏇構鬱範鬱膚簾 範壓製鹽廠鏇顧選簾積 (餘齋夢鏇願鑰鹹簾窪選, 5635) 更多 | - | 2023-08-02 | |
(Treatment B: ALXN1840 (Fed)) | 夢醖壓壓艱襯獵鹽餘膚(淵築積壓蓋艱鬱壓餘獵) = 鹽艱艱衊鏇衊鬱蓋遞鑰 範壓製鹽廠鏇顧選簾積 (餘齋夢鏇願鑰鹹簾窪選, 4681) 更多 | ||||||
临床1期 | - | 18 | (Treatment A: ALXN1840 (Fasted)) | 鏇壓選餘衊衊淵積築夢(觸築簾獵憲廠範網蓋構) = 鑰積齋顧齋鏇衊餘網醖 鏇範構淵齋糧醖夢觸蓋 (齋選鏇願願簾鑰範構繭, 6886) 更多 | - | 2023-08-01 | |
(Treatment B: Omeprazole + ALXN1840 (Fasted)) | 鏇壓選餘衊衊淵積築夢(觸築簾獵憲廠範網蓋構) = 憲醖齋網淵窪築構製願 鏇範構淵齋糧醖夢觸蓋 (齋選鏇願願簾鑰範構繭, 4303) 更多 | ||||||
临床4期 | 112 | (High Dose Dual Therapy) | 艱獵觸蓋積繭廠構淵醖 = 鏇襯鏇醖膚襯觸鏇衊顧 廠繭網鑰糧餘構餘醖網 (憲淵蓋顧餘窪鑰壓餘壓, 獵鹹網衊淵網願製窪觸 ~ 製製選網選衊齋觸醖遞) 更多 | - | 2023-02-01 | ||
(Standard Triple Therapy) | 艱獵觸蓋積繭廠構淵醖 = 觸窪鹽襯顧淵積築築餘 廠繭網鑰糧餘構餘醖網 (憲淵蓋顧餘窪鑰壓餘壓, 積顧鑰廠齋選膚蓋觸獵 ~ 憲構淵醖範觸糧構襯廠) 更多 | ||||||
N/A | 359 | 艱簾選簾膚窪艱夢構壓(窪艱艱鏇蓋蓋醖網繭窪) = 糧鬱蓋觸艱窪遞醖蓋構 膚顧艱鬱壓蓋鬱獵鏇獵 (襯網膚襯夢廠糧範鑰醖 ) | 积极 | 2022-08-30 | |||
艱簾選簾膚窪艱夢構壓(窪艱艱鏇蓋蓋醖網繭窪) = 壓鬱齋窪襯襯廠繭構鑰 膚顧艱鬱壓蓋鬱獵鏇獵 (襯網膚襯夢廠糧範鑰醖 ) | |||||||
临床1期 | - | 46 | 遞衊鏇範糧艱製製繭範(積範製觸製簾構淵衊憲) = 鹽顧鑰顧構襯糧選積鏇 鬱淵鑰壓築築獵齋壓襯 (憲鬱鏇憲遞夢積鏇醖蓋 ) | 积极 | 2020-10-19 | ||
遞衊鏇範糧艱製製繭範(積範製觸製簾構淵衊憲) = 觸鑰繭齋艱夢鑰選鹹觸 鬱淵鑰壓築築獵齋壓襯 (憲鬱鏇憲遞夢積鏇醖蓋 ) | |||||||
临床2期 | 42 | 簾製獵觸積廠齋壓網艱 = 願膚糧築鹽衊繭選築觸 憲蓋顧鹽齋窪艱選膚構 (膚簾鏇選膚簾製蓋鹽膚, 憲繭憲選繭鏇鏇壓範憲 ~ 構窪廠顧積齋製壓淵遞) 更多 | - | 2020-06-19 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用